Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China State FDA Reforms Expected, But When?

This article was originally published in PharmAsia News

Executive Summary

China's State FDA insists it will align the country's pharmaceutical and medical device regulations with international standards. The question on manufacturers' minds is, how soon

You may also be interested in...



Chinese Congress Passes New Law Covering Product Liability For Drugs And Devices, Along With Medical Malpractice

BEIJING - Chinese President Hu Jintao has signed an extensive new "Tort Law of the People's Republic of China" covering medical malpractice, product liability and related provisions that could affect companies across the life sciences with operations in China

China Grapples To Get A Handle On Reporting Mechanisms For Adverse Drug Reactions

HONG KONG - When China's State FDA released figures for cases of adverse drug reactions in late January, it touched on an underreported issue and one that may prove difficult to tackle

China Issues New Medical Device GMP Standards, Set To Take Effect On New Year's Day Of 2011

BEIJING - China's State FDA has issued a wide-ranging compilation of good manufacturing practice standards for medical devices, set to become effective one year from now, that for the first time will cover all manufacturers across the country, according to lawyers who closely monitor the sector

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC074047

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel